Professor Kensler explains their clinical trials in which chlorophyllin was administered as a therapy and the resultant levels of aflatoxin DNA damage products present in urine samples.

Thomas Kensler, Ph.D. is a professor at John Hopkins Bloomberg School of Public Health. His research focuses on the molecular mechanisms involved in the development of cancers linked to exposure to environmental carcinogens. This research has led to potential chemopreventative strategies for liver cancer in populations at high risk for aflatoxin exposure. “It's worth pointing out that in our clinical trial we didn't use vegetables to administer the chlorophyllin. We used tablets that contained 100 mg of chlorophyllin and asked our participants to take one tablet 20 minutes before each meal. We then measured for the presence of aflatoxin molecules in their blood and urine and were able to show that those people who took the chlorophyllin tablet instead of a placebo tablet had much lower levels of aflatoxin DNA damage products coming out in their urine.”

john hopkins bloomberg school of public health, bloomberg school of public health, environmental carcinogens, liver cancer, chlorophyllin, dna damage, molecular mechanisms, school of public health, aflatoxin, urine samples, high risk, clinical trial, cancers, clinical trials, molecules, mold, placebo, vegetables, mutation